Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Galizia, E. Lieto, M. Orditura, P. Castellano, A. Mura, V. Imperatore, Margherita Pinto, A. Zamboli, F. Vita, F. Ferraraccio (2007)
Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative SurgeryWorld Journal of Surgery, 31
R. Herbst (2004)
Review of epidermal growth factor receptor biology.International journal of radiation oncology, biology, physics, 59 2 Suppl
R. Siegel, Elizabeth Ward, O. Brawley, A. Jemal (2011)
Cancer statistics, 2011CA: A Cancer Journal for Clinicians, 61
F. Yakes, W. Chinratanalab, C. Ritter, W. King, S. Seelig, C. Arteaga (2002)
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.Cancer research, 62 14
J. Macdonald, S. Smalley, J. Benedetti, S. Hundahl, N. Estes, G. Stemmermann, D. Haller, J. Ajani, L. Gunderson, J. Jessup, J. Martenson (2001)
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionThe New England Journal of Medicine, 345
Yan Song, Jing Huang, Jin-wan Wang (2010)
[Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].Chinese journal of cancer, 29 1
Rebecca Fitzgerald, C. Caldas (2004)
Clinical implications of E-cadherin associated hereditary diffuse gastric cancerGut, 53
J. Rüschoff, M. Dietel, G. Baretton, S. Arbogast, A. Walch, G. Monges, M. Chenard, F. Penault-Llorca, I. Nagelmeier, W. Schlake, H. Höfler, H. Kreipe (2010)
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testingVirchows Archiv, 457
L. Klapper, H. Waterman, Michael Sela, Yosef Yarden (2000)
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.Cancer research, 60 13
C. Pinto, F. Fabio, S. Siena, S. Cascinu, F. Llimpe, C. Ceccarelli, V. Mutri, L. Giannetta, S. Giaquinta, C. Funaioli, R. Berardi, C. Longobardi, E. Piana, A. Martoni (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).Annals of oncology : official journal of the European Society for Medical Oncology, 18 3
E. Cutsem, V. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, Adriano Rodrigues, M. Fodor, Y. Chao, E. Voznyi, M. Risse, J. Ajani (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
A. Bianco (2004)
Targeting c-erbB2 and Other Receptors of the C-ErbB Family: Rationale and Clinical ApplicationsJournal of Chemotherapy, 16
A. Dassen, D. Lips, C. Hoekstra, J.R.M. Pruijt, K. Bosscha (2009)
FDG-PET has no definite role in preoperative imaging in gastric cancer.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 35 5
Y. Bang, Young-Woo Kim, Han-Kwang Yang, H. Chung, Young-Kyu Park, K. Lee, Keunsung Lee, Yong Kim, S. Noh, J. Cho, Y. Mok, Yeul-Hong Kim, J. Ji, T. Yeh, P. Button, F. Sirzén, S. Noh (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialThe Lancet, 379
B. Browne, Neil O’Brien, M. Duffy, J. Crown, N. O'Donovan (2009)
HER-2 signaling and inhibition in breast cancer.Current cancer drug targets, 9 3
T. Yano, T. Doi, A. Ohtsu, N. Boku, K. Hashizume, M. Nakanishi, A. Ochiai (2006)
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.Oncology reports, 15 1
E. Mammano, C. Belluco, Manuela Sciro, R. Mencarelli, M. Agostini, M. Michelotto, A. Marchet, D. Nitti (2006)
Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.Anticancer research, 26 5A
A. Ohtsu, M. Shah, E. Cutsem, S. Rha, A. Sawaki, Sook Park, Ho Lim, Y. Yamada, Jian Wu, B. Langer, M. Starnawski, Yoon-Koo Kang (2011)
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 30
ZA Wainberg, L.-S. Lin, B. DiCarlo, KM Dao, R. Patel, DJ Park, H. Wang, R. Elashoff, N. Ryba, J. Hecht (2011)
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junctionBritish Journal of Cancer, 105
I. Songun, H. Putter, E. Kranenbarg, M. Sasako, C. Velde (2010)
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.The Lancet. Oncology, 11 5
Y. Yamashita-Kashima, S. Iijima, K. Yorozu, K. Furugaki, M. Kurasawa, M. Ohta, K. Fujimoto‐Ouchi (2011)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft ModelsClinical Cancer Research, 17
W. Franklin, R. Veve, F. Hirsch, B. Helfrich, P. Bunn (2002)
Epidermal growth factor receptor family in lung cancer and premalignancy.Seminars in oncology, 29 1 Suppl 4
J. Dikken, J. Sandick, HA Swellengrebel, P. Lind, H. Putter, E. Jansen, H. Boot, N. Grieken, C. Velde, M. Verheij, A. Cats (2011)
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)BMC Cancer, 11
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 376
J. Lim, M. Yun, Myeong-Jin Kim, W. Hyung, Mi-Suk Park, Jin-Young Choi, Tae-sung Kim, J. Lee, S. Noh, Ki Kim (2006)
CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy.Radiographics : a review publication of the Radiological Society of North America, Inc, 26 1
C. Bozzetti, F. Negri, C. Lagrasta, P. Crafa, C. Bassano, I. Tamagnini, G. Gardini, R. Nizzoli, F. Leonardi, D. Gasparro, R. Camisa, S. Capelli, E. Silini, A. Ardizzoni (2011)
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinomaBritish Journal of Cancer, 104
D. Cunningham, W. Allum, S. Stenning, J. Thompson, C. Velde, M. Nicolson, J. Scarffe, F. Lofts, S. Falk, T. Iveson, David Smith, R. Langley, M. Verma, S. Weeden, Y. Chua, MAGIC Participants (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.The New England journal of medicine, 355 1
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
S. Lee, J. Lee, Y. Soung, Hong-Sug Kim, W. Park, S. Kim, Jong Lee, J. Park, Y. Cho, Chang Kim, S. Nam, S. Kim, Jung Lee, N. Yoo (2003)
BRAF and KRAS mutations in stomach cancerOncogene, 22
M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. Vijver, Woosuk Kim, A. Ochiai, J. Rüschoff, T. Henkel (2008)
Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 52
Y. Yarden, M. Sliwkowski (2001)
Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2
Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.
Therapeutic Advances in Medical Oncology – SAGE
Published: Jan 4, 2013
Keywords: gastric cancer,trastuzumab
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.